Status:
COMPLETED
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
Lead Sponsor:
MediPrint Ophthalmics, Inc.
Conditions:
Primary Open Angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
Eligibility Criteria
Inclusion
- Male or female, at least 18 years of age at the Screening Visit
- Diagnosed with primary open-angle glaucoma or ocular hypertension in both eyes
- At least one eye (called the study eye) must have an untreated intraocular pressure between 22 mmHg and 34 mmHg (inclusive) as measured at 9 am during the Baseline Visit.
- Best corrected visual acuity of Early Treatment Diabetic Retinopathy Study of 50 letters or better
Exclusion
- Glaucoma or optic neuropathy due to anything other than above noted reasons Cup-to-disc ratio of \>0.8 in either eye
- Corneal thickness \<480 or \>620 μm
Key Trial Info
Start Date :
January 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 16 2021
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04747808
Start Date
January 8 2021
End Date
February 16 2021
Last Update
June 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eye Research Foundatoin
Newport Beach, California, United States, 92663